Grepafloxacin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
Line 3: Line 3:
| verifiedrevid = 461123703
| verifiedrevid = 461123703
| IUPAC_name = (''RS'')-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline- 3-carboxylic acid
| IUPAC_name = (''RS'')-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline- 3-carboxylic acid
| image = Grepafloxacin.svg
| image = Grepafloxacin.png
| imagename = 1 : 1 mixture (racemate)
| imagename = 1 : 1 mixture (racemate)
| drug_name = Grepafloxacin
| drug_name = Grepafloxacin
Line 50: Line 50:
| StdInChIKey = AIJTTZAVMXIJGM-UHFFFAOYSA-N
| StdInChIKey = AIJTTZAVMXIJGM-UHFFFAOYSA-N
}}
}}
              __NOTOC__
{{SI}}
{{CMG}}
==Overview==
'''Grepafloxacin hydrochloride''' (trade name '''Raxar''', [[Glaxo Wellcome]]) was an oral broad-spectrum [[fluoroquinolone]] [[antibacterial]] agent used to treat [[bacteria]]l [[infection]]s.  Grepafloxacin was withdrawn world wide from markets in 1999,<ref name="urlwww.fda.gov">{{cite web |url=http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab5a.pdf |title= Glaxo Wellcome voluntary withdrawn Raxar (Grepafloxacin) |format= |work= |accessdate=2014-10-12}}</ref><ref name="urlLetter -Raxar">{{cite web |url=http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab5b.htm |title=Withdrawal of Product: RAXAR (grepafloxacin HCl) 600 mg Tablets, 400 mg Tablets, and 200 mg Tablets |work= U.S. Food and Drug Administation |accessdate=2014-10-12}}</ref> owing to its side effect of lengthening the [[QT interval]] on the [[electrocardiogram]], leading to cardiac events and [[Sudden cardiac death|sudden death]].<ref>{{Cite journal  | last1 = Sprandel | first1 = KA. | last2 = Rodvold | first2 = KA. | title = Safety and tolerability of fluoroquinolones. | journal = Clin Cornerstone | volume = Suppl 3 | issue =  | pages = S29-36 | year = 2003 | doi =  | PMID = 14992418 }}</ref>
'''Grepafloxacin hydrochloride''' (trade name '''Raxar''', [[Glaxo Wellcome]]) was an oral broad-spectrum [[fluoroquinolone]] [[antibacterial]] agent used to treat [[bacteria]]l [[infection]]s.  Grepafloxacin was withdrawn world wide from markets in 1999,<ref name="urlwww.fda.gov">{{cite web |url=http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab5a.pdf |title= Glaxo Wellcome voluntary withdrawn Raxar (Grepafloxacin) |format= |work= |accessdate=2014-10-12}}</ref><ref name="urlLetter -Raxar">{{cite web |url=http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab5b.htm |title=Withdrawal of Product: RAXAR (grepafloxacin HCl) 600 mg Tablets, 400 mg Tablets, and 200 mg Tablets |work= U.S. Food and Drug Administation |accessdate=2014-10-12}}</ref> owing to its side effect of lengthening the [[QT interval]] on the [[electrocardiogram]], leading to cardiac events and [[Sudden cardiac death|sudden death]].<ref>{{Cite journal  | last1 = Sprandel | first1 = KA. | last2 = Rodvold | first2 = KA. | title = Safety and tolerability of fluoroquinolones. | journal = Clin Cornerstone | volume = Suppl 3 | issue =  | pages = S29-36 | year = 2003 | doi =  | PMID = 14992418 }}</ref>


Line 59: Line 66:


==References==
==References==
{{Reflist}}
{{Reflist|2}}


{{QuinoloneAntiBiotics}}
{{QuinoloneAntiBiotics}}
Line 66: Line 73:
[[Category:Withdrawn drugs]]
[[Category:Withdrawn drugs]]
[[Category:Piperazines]]
[[Category:Piperazines]]
[[Category:Cyclopropanes]]
[[Category:Drug]]

Latest revision as of 13:01, 10 April 2015

Grepafloxacin
Clinical data
AHFS/Drugs.comMultum Consumer Information
ATC code
Pharmacokinetic data
Protein binding50%
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H22FN3O3
Molar mass359.395 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Grepafloxacin

Articles

Most recent articles on Grepafloxacin

Most cited articles on Grepafloxacin

Review articles on Grepafloxacin

Articles on Grepafloxacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Grepafloxacin

Images of Grepafloxacin

Photos of Grepafloxacin

Podcasts & MP3s on Grepafloxacin

Videos on Grepafloxacin

Evidence Based Medicine

Cochrane Collaboration on Grepafloxacin

Bandolier on Grepafloxacin

TRIP on Grepafloxacin

Clinical Trials

Ongoing Trials on Grepafloxacin at Clinical Trials.gov

Trial results on Grepafloxacin

Clinical Trials on Grepafloxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Grepafloxacin

NICE Guidance on Grepafloxacin

NHS PRODIGY Guidance

FDA on Grepafloxacin

CDC on Grepafloxacin

Books

Books on Grepafloxacin

News

Grepafloxacin in the news

Be alerted to news on Grepafloxacin

News trends on Grepafloxacin

Commentary

Blogs on Grepafloxacin

Definitions

Definitions of Grepafloxacin

Patient Resources / Community

Patient resources on Grepafloxacin

Discussion groups on Grepafloxacin

Patient Handouts on Grepafloxacin

Directions to Hospitals Treating Grepafloxacin

Risk calculators and risk factors for Grepafloxacin

Healthcare Provider Resources

Symptoms of Grepafloxacin

Causes & Risk Factors for Grepafloxacin

Diagnostic studies for Grepafloxacin

Treatment of Grepafloxacin

Continuing Medical Education (CME)

CME Programs on Grepafloxacin

International

Grepafloxacin en Espanol

Grepafloxacin en Francais

Business

Grepafloxacin in the Marketplace

Patents on Grepafloxacin

Experimental / Informatics

List of terms related to Grepafloxacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Grepafloxacin hydrochloride (trade name Raxar, Glaxo Wellcome) was an oral broad-spectrum fluoroquinolone antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn world wide from markets in 1999,[1][2] owing to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death.[3]

Clinical uses

Grepafloxacin was used for treating exacerbations of chronic bronchitis caused by susceptible bacteria (e.g. Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis),[4][5][6] community-acquired pneumonia (including those, in addition to the above germs, caused by Mycoplasma pneumoniae)[7][8] gonorrhea and non-gonococcal urethritis and cervicitis (for example caused by Chlamydia trachomatis or Ureaplasma urealyticum).[9][10]

See also

References

  1. ↑ "Glaxo Wellcome voluntary withdrawn Raxar (Grepafloxacin)" (PDF). Retrieved 2014-10-12.
  2. ↑ "Withdrawal of Product: RAXAR (grepafloxacin HCl) 600 mg Tablets, 400 mg Tablets, and 200 mg Tablets". U.S. Food and Drug Administation. Retrieved 2014-10-12.
  3. ↑ Sprandel, KA.; Rodvold, KA. (2003). "Safety and tolerability of fluoroquinolones". Clin Cornerstone. Suppl 3: S29–36. PMID 14992418.
  4. ↑ Chodosh S, Lakshminarayan S, Swarz H, Breisch S (January 1998). "Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily". Antimicrob. Agents Chemother. 42 (1): 114–20. PMC 105465. PMID 9449270. Retrieved 2014-10-12.
  5. ↑ Langan CE, Cranfield R, Breisch S, Pettit R (December 1997). "Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis". J. Antimicrob. Chemother. 40 Suppl A: 63–72. doi:10.1093/jac/40.suppl_1.63. PMID 9484875. Retrieved 2014-10-12.
  6. ↑ Langan CE, Zuck P, Vogel F, McIvor A, Peirzchala W, Smakal M, Staley H, Marr C (October 1999). "Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis". J. Antimicrob. Chemother. 44 (4): 515–23. doi:10.1093/jac/44.4.515. PMID 10588313. Retrieved 2014-10-12.
  7. ↑ O'Doherty B, Dutchman DA, Pettit R, Maroli A (December 1997). "Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia". J. Antimicrob. Chemother. 40 Suppl A: 73–81. doi:10.1093/jac/40.suppl_1.73. PMID 9484876. Retrieved 2014-10-12.
  8. ↑ Felmingham D (March 2000). "Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms". J. Antimicrob. Chemother. 45: 1–8. doi:10.1093/jac/45.suppl_2.1. PMID 10719006. Retrieved 2014-10-12.
  9. ↑ Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D (December 1997). "The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp". J. Antimicrob. Chemother. 40 Suppl A: 31–4. doi:10.1093/jac/40.suppl_1.31. PMID 9484871. Retrieved 2014-10-12.
  10. ↑ McCormack WM, Martin DH, Hook EW, Jones RB (1998). "Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection". Infect Dis Obstet Gynecol. 6 (3): 109–15. doi:10.1155/S1064744998000210. PMC 1784789. PMID 9785106. |access-date= requires |url= (help)

Template:QuinoloneAntiBiotics

Retrieved from "https://www.wikidoc.org/index.php?title=Grepafloxacin&oldid=1085714"